BRIEF—Sino-American partnership to develop and commercialize VT-1161

The USA’s Mycovia Pharmaceuticals and China’s Jiangsu Hengrui have announced an exclusive agreement to develop and commercialize Mycovia’s investigational drug, VT-1161 (otesaconazole), in China, including mainland China, Hong Kong, Macau, and Taiwan, for the treatment or prevention of a range of fungal conditions, includCommercialization, Fungal conditionsing recurrent vulvovaginal candidiasis (RVVC), onychomycosis and invasive fungal infections.

Mycovia is currently conducting global Phase III trials of VT-1161 in women with RVVC to support marketing applications in the USA, the European Union and Japan.

NovaQuest Capital Management formed Mycovia in 2018 to advance VT-1161 in global markets.

With this partnership, Mycovia is eligible to receive development funding, regulatory milestones, sales milestones and royalties on net sales of VT-1161 in China.